Portland, OR -- (SBWIRE) -- 02/28/2018 -- These are either substance, molecule or a physical event that indicate the existence of cancerous cells in the body. These molecules are generally found in tissues, urine, serum, blood, and other body fluids that indicate any abnormal process or a disease.

Cancer biomarkers are traceable substances that can be used as an indicator of biological state of tumor and thus it can be used to analyze diagnostic and prognostic stages of cancer. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach for obtaining rapid results for treatment. These biomarkers are used as risk indicators for various cancer types such as lung cancer, breast cancer, and prostate cancer among others. Some of the key biomarkers that are widely used include CEA, SCC, NSE Cyfra 21-1 and TPA (lung cancer), PSA (prostate cancer) and CA15-3, EGF R, BRCA 1/2 and Cytokeratin 14 (breast cancer).

Get the PDF of Cancer Biomarkers industry insights @ https://www.alliedmarketresearch.com/request-sample/1443

Global Cancer biomarkers market is broadly segmented based on profiling technology, biomolecules, cancer type, application, and geography. By profiling technology, the cancer biomarker industry is segmented into omic technologies, imaging technologies, immunoassays, and cytogenetics based tests. Omic technologies segment occupies the largest cancer biomarker market size. Based on biomolecules, the cancer biomarker industry is segmented into genetic biomarkers, protein biomarkers, and glycoprotein biomarkers. Genetic biomarkers occupies the largest cancer biomarker market share. The various cancer type include breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others; among which breast cancer accounts for the largest cancer biomarker market size.

Major companies have adopted collaboration and partnership as their key development strategy. The key players of the cancer biomarkers industry include F.Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Inc., Qiagen N.V. and Genomic Health, Inc. The other players in the value chain include: bioMérieux, Astellas Pharma Inc., Myriad Genetics, Epigenomics and Radient Pharmaceuticals.

Do purchase inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/1443

Key Benefits for Stakeholders:

- The projections in the report are made by analyzing the current cancer biomarkers market trends and future market potential in terms of value. The analysis helps in understanding the strategies adopted by various companies for the growth of the global cancer biomarkers market.
- Comprehensive analysis of the factors that drive and restrict the growth of the global cancer biomarkers market is provided.
- The market conditions of the global cancer biomarkers market across all regions are comprehensively analyzed.
- Porter's five forces model gives an in-depth analysis of bargaining power of buyers and suppliers, threats of new entrants and substitutes and competition amongst the key market players.
- Prime focus of the report is to reveal opportunities-analysis within this Cancer Biomarkers market with respect to cancer biomarkers industry.

Cancer Biomarkers Market Key Segments:

By Profiling Technology

- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics Based Tests

By Biomolecules

- Genetic Biomarkers
- Protein Biomarkers
- Glycoprotein Biomarkers

By Cancer Type

- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Other Cancers